Janney Montgomery Scott Reaffirms “Hold” Rating for Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “hold” rating reissued by analysts at Janney Montgomery Scott in a note issued to investors on Wednesday. They presently have a $47.00 price objective on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price target would indicate a potential upside of 23.52% from the company’s previous close.

A number of other research analysts have also issued reports on SUPN. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Piper Jaffray Companies restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Stifel Nicolaus lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price target for the company. in a report on Tuesday. They noted that the move was a valuation call. Finally, Cantor Fitzgerald restated a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a report on Tuesday. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $48.29.

Shares of Supernus Pharmaceuticals (SUPN) traded down 3.02% during midday trading on Wednesday, hitting $36.90. 1,504,976 shares of the stock traded hands. The firm’s 50-day moving average is $44.56 and its 200 day moving average is $37.95. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 18.62 and a beta of 1.30. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $50.05.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities analysts forecast that Supernus Pharmaceuticals will post $1.04 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://stocknewstimes.com/2017/09/20/janney-montgomery-scott-reaffirms-hold-rating-for-supernus-pharmaceuticals-inc-supn.html.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $49.86, for a total transaction of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares in the company, valued at approximately $623,250. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total transaction of $114,764.40. Following the sale, the vice president now directly owns 24,944 shares of the company’s stock, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 160,000 shares of company stock valued at $7,505,574. Company insiders own 6.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in SUPN. Meeder Asset Management Inc. grew its position in shares of Supernus Pharmaceuticals by 3,455.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 2,315 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $127,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 2,220 shares during the period. Riverhead Capital Management LLC grew its position in shares of Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 1,462 shares during the period. Finally, Advisor Group Inc. grew its position in shares of Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 410 shares during the period. 95.38% of the stock is owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply